MDS

I certainly am not like some people who try to present the perfect façade of their lives, but I do not want to be a downer, either.

Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.

The famous philosopher Nietzsche once said, “He who has a why to live can bear almost any how.”

While recent advances in hematology are exciting, they open the door to more questions.

Prevyis (letermovir) was granted approval by the Food and Drug Administration (FDA) to prevent cytomegalovirus (CMV) infection in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant (HSCT). The result is based on a significant reduction in CMV infection rates in a phase 3 study.

A cancer survivor talks about the importance of hope, inspired by her reading of Viktor Frankl's Man's Search for Meaning, which analyzes the psychological strength of Holocaust survivors.

A cancer survivor describes all the wonderful people she has met on her arduous journey and what they mean to her.

Sometimes we can be regarded as being obsessed with cancer, but every single cancer survivor is more than that, and hold important roles in our lives to play.

Cancer survivors generally work very hard to be healthy after a diagnosis. This article gives permission to enjoy life and have a balanced attitude toward healthy living.

How one cancer survivor attempts to cope with the reality of having chemo for the rest of her life.

Injured DNA can hide damaged blood cells in myelodysplastic syndrome (MDS).

Chemo fog, or chemo brain, is a very real phenomena that cancer survivors need to be knowledgeable about. This describes the journey of one survivor.

CURE spoke with Rami S. Komrokji, M.D. about collaborative efforts that will lead to new advances in the treatment of myelodysplastic syndrome (MDS).

In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS.

An intensive preparatory stem cell transplant (SCT) regimen should be used for younger patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), according to the results of a phase 3 clinical trial.

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

What do oncology nurses mean to their patients? This is an inside view from one grateful patient.

Revlimid is showing promise for patients with low-risk MDS, according to the results of a recent study.

High cost does not always mean better chances of survival for elderly patients with MDS, according to a recent study.

An essay honoring Emily A. Knight, RN, OCN [Mayo Clinic Cancer Center in Scottsdale, Arizona]

Ruben A. Mesa addressed the current treatment landscape for PV last week at the 33rd Annual Chemotherapy Foundation Symposium, a meeting of over 1,000 physicians and other oncology professionals.

CURE interviewed Thomas Prebet to gain insight into the importance of supportive care in myelodysplastic syndrome.

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses adverse events associated with treatment for myelodysplastic syndrome (MDS).

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses the future of treating patients with myelodysplastic syndrome (MDS).

Treatment strategies for patients with MDS are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.

Lewis Silverman, an oncologist with Mount Sinai Medical Center, discusses a clinical trial involving Revlimid (lenalidomide) for patients with a type of myelodysplastic syndrome.